GILD

Gilead Sciences, Inc. Q1 2008 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2008. Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for life-threatening diseases, primarily HIV, Hepatitis B, and fungal infections. The company operates in a single business segment and maintains significant collaborative agreements with partners such as Bristol-Myers Squibb (BMS), F. Hoffmann-La Roche Ltd (Roche), and GlaxoSmithKline (GSK).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 22% year-over-year, driven by a 36% increase in product sales. HIV product sales rose 37% to $964.7 million.
• Product Performance:
  • Truvada: Sales increased 39% to $479.4 million.
  • Atripla: Sales surged 70% to $324.2 million, accounting for 34% of total HIV sales.
  • Viread: Sales decreased 5% to $152.7 million due to patients switching to combination therapies (Truvada/Atripla).
• Royalty Decline: Royalty revenues dropped 39% to $109.5 million, primarily due to a 44% decrease in Tamiflu royalties from Roche following the fulfillment of pandemic stockpiling orders in 2007.
• Foreign Currency Impact: A weaker U.S. dollar provided a favorable impact of approximately $37.0 million on total revenues and $19.6 million on pre-tax income.
• Stock Repurchases: The company repurchased approximately 16.5 million shares for $815.8 million, including an accelerated share repurchase agreement with Goldman Sachs for $500.0 million.

Outlook, Risks, and Management Commentary

• Guidance: Management expects total product sales to continue growing in 2008. However, they anticipate full-year 2008 product gross margins will be lower than 2007 due to the higher mix of Atripla sales (which include a zero-margin component from BMS). Royalty revenues for 2008 are expected to be significantly lower than 2007 due to declining Tamiflu sales.
• Pipeline Progress:
  • Viread: Received marketing authorization in the EU for chronic hepatitis B; applications pending in the US, Australia, and Canada.
  • Aztreonam lysine: FDA target review date set for September 2008 for cystic fibrosis treatment.
  • Elvitegravir: Phase 3 dosing for this HIV integrase inhibitor is anticipated in Q3 2008.
• Risks and Contingencies:
  • Tamiflu Dependency: Pre-tax income remains disproportionately sensitive to Tamiflu royalty fluctuations.
  • Patent Challenges: Ongoing re-examination of tenofovir patents in the US and potential compulsory licensing risks in Brazil and other jurisdictions.
  • Liquidity of Auction Rate Securities: Approximately $140.3 million of the investment portfolio is held in auction rate securities (Level 3 inputs) which have experienced failed auctions. Management intends to hold these to maturity and does not anticipate a material impact on liquidity.
  • Regulatory: FDA inspection of a third-party CRO raised concerns regarding bioanalytical data, potentially requiring audits or study repetition.

Investor Verification Checklist

• Verify the sustainability of HIV product growth rates given the saturation of the market and potential for generic competition.
• Monitor the timeline and outcome of the FDA review for aztreonam lysine (target September 2008) and Viread for Hepatitis B.
• Assess the impact of declining Tamiflu royalties on future earnings stability.
• Review the status of the FDA audit regarding the third-party CRO and potential impacts on product labels or approvals.
• Track the resolution of the auction rate securities market and any potential impairment charges if liquidity needs arise.
• Confirm the progress of the accelerated share repurchase agreement settlement with Goldman Sachs.